MAR 22, 2021 8:00 AM PDT

Impact of Global Surveillance on Diagnostic Tools

Speaker
  • Head of Infectious Disease Research, Diagnostics at Abbott
    Biography

      Gavin A. Cloherty, Ph.D., is head of Infectious Disease Research for Abbott's diagnostics business. He provides scientific leadership in the area of infectious disease diagnostics by conducting groundbreaking clinical studies on hepatitis and HIV and developing new tests. As one of the top experts in the field, his innovative research is changing the way infectious diseases are being diagnosed to help improve patient outcomes. Gavin has more than 20 years of experience with Abbott and leads a team of scientists in the study of the viral diversity of HIV and hepatitis. His expertise is sought after globally through his established partnerships with commercial organizations, ministries of health, government agencies and academic institutions, such as the Centers for Disease Control and Prevention (CDC) and National Institutes of Health's AIDS Clinical Trial Group (ACTG) and Hepatitis B Research Network (HBRN). He has worked with the Republic of Georgia to help eradicate hepatitis C in the country, and is looking to expand these efforts to other regions of the world severely impacted by this disease. As a senior research scientist, Gavin assisted in the development and design of the Abbott Molecular RealTime tests and m2000 system. Throughout his career Gavin has published numerous studies, abstracts and posters. In addition to his impressive list of publications he also has been invited to speak at conferences around the world. Gavin graduated from the National University of Ireland, Galway, where he received his Ph.D. in molecular biology and a Bachelor of Science in microbiology and zoology. Gavin is a member of numerous professional and scientific societies, including the International AIDS Society and the American Association for the Study of Liver Disease. He also is a contributor to multiple editorial boards, including the Journal of Clinical Microbiology and Journal of Clinical Virology.


    Abstract

    Date:  March 22, 2021

    Time: 8:00am PDT,  11:00am EDT

     

    Viral diversity presents an ongoing challenge for diagnostic tests, which must be designed to accurately detect all current and future circulating strains.  High level of viral genetic diversity has important implications for patient management as number of diagnostic tests from screening, diagnosis to monitoring are critical for the continuum of care.  Recognizing the importance of this issue, twenty eight years ago Abbott initiated a comprehensive program to monitor global diversification of certain pathogens and search for newly emerging variants, assemble large volume panels of genetically and geographically diverse strains, and develop strategies to determine the impact of viral diversity on assays used for detecting and monitoring infection. Over the course of the SARS-CoV-2 pandemic, the Abbott Global Surveillance program has been closely monitoring variants of concern and their impact on diagnostic assay performance.  In addition to viral pathogen monitoring, this team also identifies and develops emerging diagnostic disease markers such as HBV RNA.  Recently, the program expanded its expertise and formed a first-of-its-kind global scientific and public-health partnership dedicated to the early detection of, and rapid response to, future pandemic threats.

     

    Learning Objectives:

    • Discuss and better understand viral diversity and the impact it has on diagnostic tools

    • Explore SARS-CoV-2 surveillance: Where are we at today?

    • Discuss HBV DNA or RNA for patient management

    • Discuss how to stay ahead of the next pandemic with Abbott’s Pandemic Defense Coalition

     

     

    Webinars will be available for unlimited on-demand viewing after live event.

     

    LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.


    Show Resources
    You May Also Like
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JAN 21, 2021 8:00 AM PST
    JAN 21, 2021 8:00 AM PST
    Date: January 21, 2021 Time: 8:00am (PST), 11:00am (EST) Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g.,...
    APR 21, 2021 10:00 AM PDT
    C.E. CREDITS
    APR 21, 2021 10:00 AM PDT
    Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    DEC 15, 2020 10:00 AM PST
    C.E. CREDITS
    DEC 15, 2020 10:00 AM PST
    DATE: December 15, 2020 TIME: 10:00am PST Scientists from Thermo Fisher Scientific will walk us through the world of microorganisms. They will discuss their most recent research on viruses,...
    Loading Comments...
    Show Resources
    Attendees
    • See more